TY - JOUR
T1 - Association of Dual LRRK2 G2019S and GBA Variations with Parkinson Disease Progression
AU - Ortega, Roberto A.
AU - Wang, Cuiling
AU - Raymond, Deborah
AU - Bryant, Nicole
AU - Scherzer, Clemens R.
AU - Thaler, Avner
AU - Alcalay, Roy N.
AU - West, Andrew B.
AU - Mirelman, Anat
AU - Kuras, Yuliya
AU - Marder, Karen S.
AU - Giladi, Nir
AU - Ozelius, Laurie J.
AU - Bressman, Susan B.
AU - Saunders-Pullman, Rachel
N1 - Funding Information:
Conflict of Interest Disclosures: Dr Wang reported grants from the National Institutes of Health (NIH) outside the submitted work. Dr Thaler reported receiving personal fees from Abbvie outside the submitted work. Dr Alcalay reported receiving personal fees from Sanofi and Janssen outside the submitted work. Dr West reported receiving personal fees from the Michael J. Fox foundation, grants from the Michael J. Fox foundation, Biogen, and Escape Bio, and having a patent for EP2844660B1 outside the submitted work; in addition. Dr Mirelman reported receiving personal fees from Neuroderm Consulting outside the submitted work. Dr Marder reported receiving grants from the Michael J Fox Foundation, the NIH, and Parkinson’s Foundation outside the submitted work. Dr Giladi reported receiving personal fees from Sionara, NeuroDerm, Pharma2B, Denali, Neuron23, Sanofi-Genzyme, Biogen, Abbvie, Lysosomal Therapeutics, Movement Disorder Society and grants from the Michael J Fox Foundation, Parkinson’s Foundation, European Union, Israel Science Foundation, Teva National Network of Excellence program, Biogen, Ionis, Sieratzki Family Foundation, and Aufzien Academic Center in Tel-Aviv University outside the submitted work. Dr Bressman reported grants from Michael J Fox Foundation outside the submitted work. No other disclosures were reported.
Funding Information:
Funding/Support: This study was supported by National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) (grant Nos. U01 NS107016 and U01 NS094148), and the Bigglesworth Family Foundation, Bachman-Strauss Chair.
Funding Information:
Additional Contributions: Data and biospecimens used in preparation of this manuscript were obtained from the Parkinson’s Disease Biomarkers Program (PDBP) Consortium, supported by the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. Investigators in the PDBP Consortium include Roger Albin, Roy Alcalay, Alberto Ascherio, Thomas Beach, Sarah Berman, Bradley Boeve, F. DuBois Bowman, Shu Chen, Alice Chen-Plotkin, William Dauer, Ted Dawson, Paula Desplats, Richard Dewey, Ray Dorsey, Jori Fleisher, Kirk Frey, Douglas Galasko, James Galvin, Dwight German, Lawrence Honig, Xuemei Huang, David Irwin, Kejal Kantarci, Anumantha Kanthasamy, Daniel Kaufer, James Leverenz, Carol Lippa, Irene Litvan, Oscar Lopez, Jian Ma, Lara Mangravite, Karen Marder, Laurie Orzelius, Vladislav Petyuk, Judith Potashkin, Liana Rosenthal, Rachel Saunders-Pullman, Clemens Scherzer, Michael Schwarzschild, Tanya Simuni, Andrew Singleton, David Standaert, Debby Tsuang, David Vaillancourt, David Walt, Andrew West, Cyrus Zabetian, Jing Zhang, and Wenquan Zou. The PDBP Investigators, with exception of Drs Alcalay, Marder, Ozelius, Saunders-Pullman, Scherzer and West have not participated in reviewing the data analysis or content of the manuscript. The Harvard Biomarkers Study (HBS) is a collaborative initiative of Brigham and Women’s Hospital and Massachusetts General Hospital, codirected by Clemens Scherzer and Bradley T. Hyman. HBS investigators are listed at https://www.bwhparkinsoncenter.org. The HBS Investigators have not participated in reviewing the current manuscript. The HBS Study Investigators include codirectors: Clemens R. Scherzer (Brigham and Women’s Hospital) and Bradley T. Hyman (Massachusetts General Hospital); investigators and study coordinators: Yuliya Kuras, Karbi Choudhury, Michael T. Hayes, Aleksandar Videnovic, Nutan Sharma, Vikram Khurana, Claudio Melo De Gusmao, and Reisa Sperling (Brigham and Women’s Hospital); and John H. Growdon, Michael A. Schwarzschild, Albert Y. Hung, Alice W. Flaherty, Deborah Blacker, Anne-Marie Wills, Steven E. Arnold, Ann L. Hunt, Nicte I. Mejia, Anand Viswanathan, Stephen N. Gomperts, Mark W. Albers, Maria Allora-Palli, David Hsu, Alexandra Kimball, Scott McGinnis, John Becker, Randy Buckner, Thomas Byrne, Maura Copeland, Bradford Dickerson, Matthew Frosch, Theresa Gomez-Isla, Steven Greenberg, Julius Hedden, Elizabeth Hedley-Whyte, Keith Johnson, Raymond Kelleher, Aaron Koenig, Maria Marquis-Sayagues, Gad Marshall, Sergi Martinez-Ramirez, Donald McLaren, Olivia Okereke, Elena Ratti, Christopher William, Koene Van Dij, Shuko Takeda, Anat Stemmer-Rachaminov, Jessica Kloppenburg, Catherine Munro, Rachel Schmid, Sarah Wigman, Sara Wlodarcsyk (Massachusetts General Hospital); data coordination: Thomas Yi (Brigham and Women’s Hospital); and biobank management staff: Idil Tuncali (Brigham and Women’s Hospital). Data used in preparation of this study were obtained from the Michael J. Fox Foundation–sponsored LRRK2 Cohort Consortium. The LRRK2 Cohort Consortium is coordinated and funded by The Michael J. Fox Foundation for Parkinson’s Research. Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database PPMI, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, and the full names of all of the PPMI funding partners can be found at found at www.ppmi-info.org/fundingpartners.
Publisher Copyright:
© 2021 American Medical Association. All rights reserved.
PY - 2021/4/21
Y1 - 2021/4/21
N2 - Importance: Despite a hypothesis that harboring a leucine-rich repeat kinase 2(LRRK2) G2019S variation and a glucocerebrosidase (GBA) variant would have a combined deleterious association with disease pathogenesis, milder clinical phenotypes have been reported in dual LRRK2 and GBA variations Parkinson disease (PD) than in GBA variation PD alone. Objective: To evaluate the association of LRRK2 G2019S and GBA variants with longitudinal cognitive and motor decline in PD. Design, Setting, and Participants: This longitudinal cohort study of continuous measures in LRRK2 PD, GBA PD, LRRK2/GBA PD, and wild-type idiopathic PD used pooled annual visit data ranging from 2004 to 2019 from the Mount Sinai Beth Israel, Parkinson Disease Biomarker Program, Harvard Biomarkers Study, Ashkenazi Jewish-LRRK2-Consortium, Parkinson Progression Marker Initiative, and SPOT-PD studies. Patients who were screened for GBA and LRRK2 variations and completed either a motor or cognitive assessment were included. Data were analyzed from May to July 2020. Main Outcomes and Measures: The associations of LRRK2 G2019S and GBA genotypes on the rate of decline in Montreal Cognitive Assessment (MoCA) and Movement Disorders Society-Unified Parkinson Disease Rating Scale-Part III scores were examined using linear mixed effects models with PD duration as the time scale. Results: Among 1193 individuals with PD (mean [SD] age, 66.6 [9.9] years; 490 [41.2%] women), 128 (10.7%) had GBA PD, 155 (13.0%) had LRRK2 PD, 21 (1.8%) had LRRK2/GBA PD, and 889 (74.5%) had idiopathic PD. Patients with GBA PD had faster decline in MoCA than those with LRRK2/GBA PD (B [SE], -0.31 [0.09] points/y; P <.001), LRRK2 PD (B [SE], -0.33 [0.09] points/y; P <.001), or idiopathic PD (B [SE], -0.23 [0.08] points/y; P =.005). There was a LRRK2 G2019S × GBA interaction in MoCA decline (B [SE], 0.22 [0.11] points/y; P =.04), but not after excluding severe GBA variations (B [SE], 0.12 [0.11] points/y; P =.28). Patients with GBA PD had significantly worse motor progression compared with those with idiopathic PD (B [SE], 0.49 [0.22] points/y; P =.03) or LRRK2 PD (B [SE], 0.77 [0.26] points/y; P =.004). Conclusions and Relevance: These findings suggest that longitudinal cognitive decline in patients with GBA PD was more severe than in those with LRRK2/GBA PD, which more closely resembled LRRK2 PD. This further supports the notion of a dominant association of LRRK2 on GBA in individuals who carry both and raises the possibility of an LRRK2 × GBA interaction. However, the biological basis of a dominant association or interaction is not clear and is apparently contrary to basic investigations. Study of a larger cohort of individuals with severe GBA variation is warranted..
AB - Importance: Despite a hypothesis that harboring a leucine-rich repeat kinase 2(LRRK2) G2019S variation and a glucocerebrosidase (GBA) variant would have a combined deleterious association with disease pathogenesis, milder clinical phenotypes have been reported in dual LRRK2 and GBA variations Parkinson disease (PD) than in GBA variation PD alone. Objective: To evaluate the association of LRRK2 G2019S and GBA variants with longitudinal cognitive and motor decline in PD. Design, Setting, and Participants: This longitudinal cohort study of continuous measures in LRRK2 PD, GBA PD, LRRK2/GBA PD, and wild-type idiopathic PD used pooled annual visit data ranging from 2004 to 2019 from the Mount Sinai Beth Israel, Parkinson Disease Biomarker Program, Harvard Biomarkers Study, Ashkenazi Jewish-LRRK2-Consortium, Parkinson Progression Marker Initiative, and SPOT-PD studies. Patients who were screened for GBA and LRRK2 variations and completed either a motor or cognitive assessment were included. Data were analyzed from May to July 2020. Main Outcomes and Measures: The associations of LRRK2 G2019S and GBA genotypes on the rate of decline in Montreal Cognitive Assessment (MoCA) and Movement Disorders Society-Unified Parkinson Disease Rating Scale-Part III scores were examined using linear mixed effects models with PD duration as the time scale. Results: Among 1193 individuals with PD (mean [SD] age, 66.6 [9.9] years; 490 [41.2%] women), 128 (10.7%) had GBA PD, 155 (13.0%) had LRRK2 PD, 21 (1.8%) had LRRK2/GBA PD, and 889 (74.5%) had idiopathic PD. Patients with GBA PD had faster decline in MoCA than those with LRRK2/GBA PD (B [SE], -0.31 [0.09] points/y; P <.001), LRRK2 PD (B [SE], -0.33 [0.09] points/y; P <.001), or idiopathic PD (B [SE], -0.23 [0.08] points/y; P =.005). There was a LRRK2 G2019S × GBA interaction in MoCA decline (B [SE], 0.22 [0.11] points/y; P =.04), but not after excluding severe GBA variations (B [SE], 0.12 [0.11] points/y; P =.28). Patients with GBA PD had significantly worse motor progression compared with those with idiopathic PD (B [SE], 0.49 [0.22] points/y; P =.03) or LRRK2 PD (B [SE], 0.77 [0.26] points/y; P =.004). Conclusions and Relevance: These findings suggest that longitudinal cognitive decline in patients with GBA PD was more severe than in those with LRRK2/GBA PD, which more closely resembled LRRK2 PD. This further supports the notion of a dominant association of LRRK2 on GBA in individuals who carry both and raises the possibility of an LRRK2 × GBA interaction. However, the biological basis of a dominant association or interaction is not clear and is apparently contrary to basic investigations. Study of a larger cohort of individuals with severe GBA variation is warranted..
UR - http://www.scopus.com/inward/record.url?scp=85104966273&partnerID=8YFLogxK
U2 - 10.1001/jamanetworkopen.2021.5845
DO - 10.1001/jamanetworkopen.2021.5845
M3 - Article
C2 - 33881531
AN - SCOPUS:85104966273
SN - 2574-3805
VL - 4
JO - JAMA network open
JF - JAMA network open
IS - 4
M1 - e215845
ER -